Boston Scientific Corporation updated the prescribing information for its Varithena (polidocanol) injectable foam on October ...
In Japan, where heart disease is the second leading cause of death (220,444 deaths in 2025), it was introduced on X that ...
Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...
During the October 1 episode of Mad Money, Jim Cramer discussed Amgen Inc. (NASDAQ:AMGN) while reviewing the Dow Jones ...
Amgen enters October with fresh Phase 3 pipeline wins, strong growth from Repatha and Imdelltra, and MariTide advancing ...
Approval builds on established role of Rhapsido in CSU and highlights potential of BTK inhibition across immune-mediated ...
The FDA approved remibrutinib (Rhapsido; Novartis) today, October 7, 2026, as the first treatment for adults with symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results